INTRODUCTION
Primary central nervous system (CNS) lymphoma is a rare and aggressive extranodal non-Hodgkin lymphoma. It is confined to the brain, eyes, spinal cord, or leptomeninges without systemic involvement at the time of diagnosis. It accounts for approximately 2% of all CNS tumors, with an overall incidence rate of 0.43 per 100,000 population. 1 Among patients who are immunocompetent, primary CNS lymphoma typically affects older adults, and the median age at diagnosis is 66 years. CNS lymphoma in men and women older than 65 years of age continues to increase.
2
Treatment for primary CNS lymphoma has advanced greatly in the past 2 decades, and long-term survival is observed in about 15% to 20% of patients after high-dose methotrexatebased chemotherapy with or without radiation therapy, particularly in younger patients and those with good performance status. However, the 5-year survival rate remains low at 33%. 1 Untreated, primary CNS lymphoma carries a very poor prognosis, with an overall survival of approximately 1.5 months.
This article provides an overview of the clinical features, diagnosis, pathology, and management of primary CNS lymphoma in patients who are immunocompetent, focusing on recent advances in treatment. Primary CNS lymphoma in patients who are immunocompromised, such as those with acquired immunodeficiency syndrome (AIDS) associated with human immunodeficiency virus (HIV), differs with regard to epidemiology, clinical and neuroimaging features, and management and will not be discussed in this article.
CLINICAL FEATURES
The presenting symptoms of primary CNS lymphoma are variable, depending on the site of the CNS involved. Common symptoms include cognitive or behavioral changes lasting from weeks to months, focal neurologic deficits, and symptoms of increased intracranial pressure. Seizures are uncommon, as primary CNS lymphoma tends to involve deep brain structures. Approximately 10% to 20% of patients with primary CNS lymphoma will have concurrent ocular (retina, choroid, or vitreous) involvement and may present with ocular symptoms such as floaters or blurred vision. However, up to half of patients with eye involvement have no ocular symptoms. 3 Primary vitreoretinal lymphoma is rare, with approximately 300 new cases diagnosed each year. Concurrent leptomeningeal involvement occurs in about 15% to 20% of patients with primary CNS lymphoma. 4 It is often asymptomatic and only detected after baseline CSF evaluation of newly diagnosed primary CNS lymphoma. The rarest manifestation of primary CNS lymphoma is spinal cord lymphoma, which presents with symptoms that correspond to the level of the spinal cord involvement. 5 
DIAGNOSIS
Primary CNS lymphoma in patients who are immunocompetent presents as a solitary intracranial lesion in up to 70% of affected patients. It typically occurs in the supratentorial region, with a predilection to involve the periventricular white matter. The most common sites include the cerebral hemisphere (38%), basal ganglia and thalamus (16%), and corpus callosum (14%). 6 Disease confined to the CSF, eye, or spinal cord at presentation is rare. 7 Neuroimaging MRI with gadolinium is the preferred imaging modality in the diagnosis of primary CNS lymphoma. Primary CNS lymphoma is characterized by homogeneous contrast enhancement with well-defined borders.
6 Nonenhancing lesions are rare. Perilesional edema, typically vasogenic in nature, is common. Isointense to hypointense appearance on T2-weighted MRI and restricted diffusion on diffusion-weighted imaging (DWI), which are other characteristics of primary CNS lymphoma, are explained by its high cellularity, with tightly compacted cells and a high nuclear to cytoplasmic ratio. 8 These radiographic features may help to differentiate primary CNS lymphoma from other conditions that are in the radiographic differential diagnosis, such as infections, tumefactive demyelinating lesions, or gliomas. 9 Radiographic response to corticosteroids is common and does not secure the diagnosis of primary CNS lymphoma, as inflammatory or demyelinating conditions show response as well. Rarely, primary CNS lymphoma may present with subtle focal abnormalities of cranial or radicular nerves or focal meningeal enhancement.
Recently, studies of advanced imaging techniques, such as quantitative DWI and perfusion MRI, have demonstrated the usefulness of these metrics in diagnosis and prognostication. 8 These newer techniques may ultimately provide noninvasive imaging biomarkers that might identify patients with primary CNS lymphoma who are at risk for poor outcome and may facilitate individualized treatment plans in the future.
Histopathology
Histopathologic diagnosis is essential and is typically made by stereotactic brain biopsy. Occasionally, CSF cytology and flow cytometry or vitrectomy or chorioretinal biopsy may be sufficient to make a definitive diagnosis, thereby avoiding brain biopsy. It is important to avoid corticosteroids before biopsy when primary CNS lymphoma is suspected, as corticosteroids can interfere with histopathologic diagnosis and cause significant diagnostic delays. In patients with significant cerebral edema or increased intracranial pressure, administration of mannitol may be considered prior to biopsy. Once diagnostic biopsy has been performed, corticosteroids may be commenced as required.
More than 90% of primary CNS lymphoma cases are diffuse large B-cell lymphoma, with the remainder consisting of T-cell (2%), Burkitt, lymphoblastic, and low-grade lymphomas. 10 Primary CNS diffuse large B-cell lymphoma is recognized as a distinct subtype of diffuse large B-cell lymphoma in the World Health Organization (WHO) classification 11 and expresses pan B-cell antigens (CD19, CD20, and CD79a). 10, 12 Melanoma associated antigen (mutated) 1 (MUM1)/interferon regulatory factor 4 (IRF4) is nearly always positive, B-cell CLL/lymphoma 6 (BCL6) is expressed in about 50% of cases, B-cell CLL/lymphoma 2 (BCL2) is variably expressed, and CD10 is expressed in only a small minority of cases. 10, 12 This means the majority of primary CNS diffuse large B-cell lymphomas have a postgerminal center or an activated B-cell immunophenotype. BCL6, CD10, BCL2, MUM1/IRF4, and Ki-67 may have prognostic importance but with somewhat conflicting data from mostly small or retrospective studies. Further prospective studies evaluating these markers as prognostic factors are warranted. 13 
BASELINE EVALUATIONS
In addition to a contrast-enhanced MRI or CT scan (when MRI is contraindicated) of the brain, comprehensive baseline evaluations, as outlined in Table 5 -1, are recommended.
14 The extent of disease should be evaluated with CSF analysis, slit-lamp examination of both eyes, and contrast-enhanced MRI of the entire spine. Systemic disease should be excluded by positron emission tomography (PET)/CT (chest/abdomen/pelvis), bone marrow biopsy, and, for men, testicular ultrasound. Corticosteroid dosing should be recorded, as treatment response assessment may be affected by corticosteroid use.
PROGNOSTIC FEATURES
The two most important prognostic factors for primary CNS lymphoma are age and performance status. Two prognostic scoring systems have been developed specifically for primary CNS lymphoma. In an international retrospective cohort of 378 patients with primary CNS lymphoma who were immunocompetent, the International Extranodal Lymphoma Study Group (IELSG) identified age, Eastern Cooperative Oncology Group (ECOG) performance status (see Appendix A), serum lactate dehydrogenase level, CSF protein concentration, and involvement of deep structures of the brain to be independent survival predictors. 15 The final scores according to the IELSG scoring system and their corresponding 2-year overall survival rates are presented in Memorial Sloan Kettering Cancer Center prognostic model is the other scoring system. This was derived from a retrospective analysis of 338 patients and identified age and Karnofsky Performance Status Scale score as the only independent prognostic factors. 16 The three patient groups stratified in this scoring system and their survival rates are presented in Table 5 with acute symptoms of brain herniation. In such rare cases, tumor debulking might be beneficial to improve symptoms and tolerance to upcoming intensive chemotherapy.
Whole-brain Radiation Therapy and Delayed Neurotoxicity
Primary CNS lymphoma is highly sensitive to radiation, and whole-brain radiation therapy was the standard therapy for this disease until high-dose methotrexate was shown to improve survival in the 1970s. Despite high response rates to whole-brain radiation therapy, early relapse was seen in the majority of patients, with a median overall survival of 12 to 18 months. 18 Whole-brain radiation therapyYrelated delayed neurotoxicity is a major problem in survivors, especially patients older than 60 years of age, causing significant morbidities including cognitive impairment, incontinence, and gait disturbance. A significant decline in Karnofsky Performance Status Scale score (20 to 50 points) with a marked reduction in quality of life has been observed in several studies, especially in patients 60 years of age and older.
19,20
KEY POINT h Whole-brain radiation therapyYrelated delayed neurotoxicity is a major problem in survivors of primary central nervous system lymphoma, causing significant morbidities including cognitive impairment, incontinence, and gait disturbance. Case 5-1
A 66-year-old man with a history of hypertension and hyperlipidemia presented with an acute deterioration in speech. He first noted an inability to read, and his wife noted that he was not making sense when he spoke. He had no other neurologic symptoms. Brain MRI confirmed two homogenously enhancing lesions in the splenium of the corpus callosum and in the left parietooccipital junction with associated restricted diffusion ( Figure 5-1A) . He underwent stereotactic biopsy of the left parietooccipital lesion. The histology findings were consistent with diffuse large B-cell lymphoma with FIGURE 5-1 Brain MRI of the patient in Case 5-1 (contrast-enhanced T1-weighted images on left and diffusion-weighted images on right). Axial MRIs show two homogenously enhancing lesions in the splenium of the corpus callosum and in the left parietooccipital junction (A, B). First MRI after starting treatment with high-dose methotrexate, temozolomide, and rituximab shows mixed response, with reduction of the left parietooccipital lesion and enlargement of the corpus callosum lesion (C, D). Based on this, treatment was changed to a high-dose methotrexate/cytarabine combination, with which the patient achieved a complete radiographic response (E, F).
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On MRI, treatment-related neurotoxicity manifests as white matter abnormalities, ventricular enlargement, and cortical atrophy. The extent of radiographic abnormality appears to correlate with clinical cognitive dysfunction. 19 The mechanism of radiation therapyYrelated neurotoxicity remains unclear but may involve toxicity to blood vessels, demyelination, and depletion of neural progenitor cells from the subventricular zone. 21Y23 Currently, no preventive measures or treatments exist to reverse these neurotoxic effects. Because of its inadequate control of the disease and its deleterious neurotoxicity, wholebrain radiation therapy alone is no longer recommended for newly diagnosed primary CNS lymphoma in patients who are elderly and should be used cautiously in all patients.
Chemotherapy and Multimodality Therapy
In the 1970s, high-dose methotrexate was recognized as the most effective treatment for primary CNS lymphoma. Studies of single-agent high-dose IV methotrexate (3.5 g/m 2 to 8 g/m 2 ) demonstrated overall response rates of 35% to 74%, median progression-free survival of 10 to 12.8 months, and median overall survival of 25 to 55 months. 24Y26 When high-dose methotrexate was combined with other chemotherapeutic agents, tumor response and survival outcomes improved further. A large range of survival outcomes exists across studies of combination chemotherapy owing to the different regimens and dosing programs used in these studies ( Table 5-5) . 24Y34 Agents studied in addition to methotrexate include temozolomide, rituximab, procarbazine, cytarabine, thiotepa, vincristine, carmustine, etoposide, ifosfamide, and cyclophosphamide. For example, in a multicenter randomized phase 2 trial of high-dose methotrexate with or without high-dose cytarabine followed by consolidative whole-brain radiation therapy in all patients, the complete radiographic response rate (46% versus 18%), 3-year progression-free survival (38% versus 21%), and 3-year overall survival (46% versus 32%) were all improved by KEY POINTS h Because of its inadequate control of the disease and its deleterious neurotoxicity, whole-brain radiation therapy alone is no longer recommended for newly diagnosed primary central nervous system lymphoma.
h High-dose methotrexate-based combination chemotherapy is considered the standard initial induction therapy for newly diagnosed primary central nervous system lymphoma.
nongerminal center phenotype. Evaluation with spine MRI and slit-lamp examination of the eyes showed no involvement of the spine or the eyes. Full body positron emission tomography (PET)/CT and bone marrow biopsy were negative for systemic lymphoma. However, CSF cytology and flow cytometry showed malignant cells consistent with CSF involvement by diffuse large B-cell lymphoma. Human immunodeficiency virus (HIV) serology was negative. His renal function was good. He started treatment with high-dose IV methotrexate (8 g/m 2 ), temozolomide, and rituximab, but later changed to high-dose methotrexate and high-dose cytarabine when the first MRI assessment showed mixed response, with reduction of the left occipital tumor and enlargement of the splenium tumor ( Figure 5-1B) . He achieved a complete radiographic response as well as clearance of CSF with the latter regimen ( Figure 5-1C) . His presenting neurologic symptoms completely resolved. He then proceeded to consolidative autologous stem cell transplantation with conditioning thiotepa, busulfan, and cyclophosphamide chemotherapy. He remained recurrence free at his 4-year-follow-up.
Comment. This case illustrates how primary central nervous system (CNS) lymphoma can mimic glioblastoma with regard to clinical presentation and brain imaging. A rapid and thorough workup in this patient revealed the diagnosis of primary CNS diffuse large B-cell lymphoma with CSF involvement, and the patient was treated successfully. This case also illustrates the importance of close monitoring and modification of treatment according to the disease response to treatment. Although primary CNS lymphoma is aggressive and can lead to death in a short number of months if untreated, long-term survival is possible after a prompt diagnosis and appropriate treatment.
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adding cytarabine to methotrexate as induction treatment. 27 In a 2016 randomized phase 2 trial, the addition of thiotepa and rituximab to high-dose methotrexate/cytarabine (MATRix regimen) improved the complete radiographic response rate (49% versus 23%), 2-year progression-free survival (61% versus 36%), and 2-year overall survival (69% versus 42%). 28 Based on these observations, it is generally agreed that initial induction therapy should include high-dose methotrexate-based combination chemotherapy. However, no consensus exists on the optimal dose and schedule of high-dose methotrexate or the optimal chemotherapy combination. The role of intrathecal chemotherapy (methotrexate or cytarabine) as CSF prophylaxis or treatment in patients with primary CNS lymphoma is even less clear, as prospective data of its use are limited and retrospective studies failed to show any additional benefit. However, it could be considered in patients with documented CSF involvement with primary CNS lymphoma and insufficient response to high-dose IV methotrexate-based chemotherapy. The role of additional consolidative wholebrain radiation therapy in patients with newly diagnosed primary CNS lymphoma also remains debatable.
In an effort to prevent delayed neurotoxicity of whole-brain radiation therapy, recent studies have focused on either reducing or deferring wholebrain radiation therapy until recurrence. A multicenter phase 2 trial evaluated chemoimmunotherapy consisting of rituximab, methotrexate, procarbazine, and vincristine (R-MPV regimen) followed by consolidative reduced-dose whole-brain radiation therapy of 23.4 Gy and cytarabine in patients who had achieved a complete radiographic response after the induction chemotherapy. 29 In patients who achieved a complete radiographic response and received all planned treatment, the median progression-free survival was 7.7 years, and the 3-year overall survival was 87%. The median overall survival was not reached for this group, with a median follow-up of 6 years. Comprehensive neuropsychological testing in this study showed improvement in baseline executive function and verbal memory after induction chemotherapy attributable to tumor response and relatively stable scores at 48 months of follow-up. Similar results were observed in another multicenter phase 2 trial that investigated multiagent initial chemoimmunotherapy consisting of highdose methotrexate, temozolomide, and rituximab (MTR regimen) followed by hyperfractionated wholebrain radiation therapy (36 Gy), then postYradiation therapy maintenance temozolomide for a further 10 months. 30 Longer neuropsychological follow-up is necessary to definitively address the safety of these treatment regimens using lower-dose consolidative whole-brain radiation therapy.
Other studies have omitted wholebrain radiation therapy from the treatment of patients with newly diagnosed primary CNS lymphoma. In a multicenter randomized phase 3 trial, patients were randomly assigned to receive high-dose methotrexate-based chemotherapy with or without consolidative whole-brain radiation therapy (45 Gy). 31 This was a noninferiority study, and the whole-brain radiation therapy arm had a high dropout rate. While 2-year progression-free survival was prolonged with whole-brain radiation therapy compared to chemotherapy alone (43.5% versus 30.7%), no overall survival difference was seen (32.4 months versus 37.1 months). 35 Neurotoxicity was more common in the radiation therapy group (49% versus 26%). These findings suggested that omitting whole-brain radiation therapy from the initial treatment of primary CNS lymphoma may not compromise overall survival and preserves neurologic function. However, the noninferiority end point was not statistically significant in this study.
More recently, a multicenter phase 2 trial of an induction MTR regimen followed by consolidative etoposide/ cytarabine combination without wholebrain radiation therapy reported a complete radiographic response rate after induction therapy of 66% and a median progression-free survival of 29 months. 32 Median overall survival was not reached at a median follow-up of 5 years. These results are comparable to those seen with consolidative whole-brain radiation therapy. A randomized phase 2 study (Radiation Therapy Oncology Group [RTOG] 1114) comparing the R-MPV regimen with or without reduceddose whole-brain radiation therapy (23.4 Gy) followed by cytarabine is currently ongoing (NCT01399372). 36 High-dose chemotherapy followed by autologous stem cell transplantation is another nonYwhole-brain radiation therapyYcontaining consolidative approach. This involves leukapheresis and peripheral blood stem cell harvest followed by conditioning high-dose chemotherapy, then reinfusion of the stem cells to restore blood cell production. Because of the various chemotherapies used in clinical trials, no consensus exists on the optimal regimen. However, conditioning regimens that contain CNS-penetrant agents, such as carmustine, thiotepa, cyclophosphamide, busulfan, high-dose cytarabine, KEY POINT h The optimal dose and schedule of high-dose methotrexate or the optimal chemotherapy combination has yet to be defined, and the role of additional consolidative reduced-dose whole-brain radiation therapy in patients with newly diagnosed primary central nervous system lymphoma also remains unclear. and etoposide, have demonstrated the most encouraging results. Two phase 2 trials of this approach showed highly promising 2-year overall survival. In a multicenter phase 2 study of induction chemotherapy consisting of high-dose methotrexate, cytarabine, thiotepa, and rituximab, followed by high-dose carmustine and thiotepa conditioning with autologous stem cell transplantation, the overall response rate was 91%, and the 2-year overall survival was 87%. 33 The treatment-related mortality rate was less than 10%. In another phase 2 study, patients who responded to an induction R-MPV regimen were treated with consolidative high-dose chemotherapy consisting of thiotepa, busulfan, and cyclophosphamide (TBC regimen) followed by autologous stem cell transplantation. 34 With a median follow-up of 45 months, median progression-free survival and overall survival were not reached. Two-year progression-free survival and overall survival were 79% and 81%, respectively. In this study, however, treatmentrelated death among patients who received autologous stem cell transplantation was high at 11.5%. Long-term survival data from another phase 2 trial, in which patients received high-dose methotrexate, then high-dose busulfan and thiotepa followed by autologous stem cell transplantation, showed a durable response with an overall survival rate of 35% after 10 years of follow-up. 37 Moreover, seven of the eight patients who were treated with chemotherapy alone had no neurotoxicity and had excellent quality of life and health condition, with Karnofsky Performance Status Scale scores of 90% to 100%. Overall, high-dose chemotherapy followed by autologous stem cell transplantation appears to be highly effective, with less delayed neurotoxicity; therefore, it is a promising consolidative approach, especially in younger patients with good performance status. Several ongoing randomized trials are comparing the efficacy of different consolidation approaches (high-dose chemotherapy followed by autologous stem cell transplantation versus chemotherapy or whole-brain radiation therapy).
Elderly Patients
Patients older than 60 years of age account for more than half of all primary CNS lymphoma cases. Age has been identified as an independent poor prognostic factor. Moreover, the risk of neurotoxicity is highest in patients who are elderly, and the majority of them develop significant neurotoxicity after a whole-brain radiation therapyYcontaining regimen. Recently a meta-analysis of 783 elderly patients with newly diagnosed primary CNS lymphoma was reported. 38 In this study, 73% of patients received highdose methotrexate-based chemotherapy, with a median dose of 3 g/m 2 . Any high-dose methotrexate-based therapy was associated with improved survival, especially when combined with oral alkylating agents such as procarbazine or temozolomide. More aggressive IV chemotherapy regimens were not superior. Although the addition of whole-brain radiation therapy was associated with better survival outcomes, it was also associated with an increased risk of neurotoxicity (odds ratio of 5.23).
No established standard of care exists for patients who are elderly; however, it is recommended to omit or defer whole-brain radiation therapy to disease relapse and to consider multiagent chemotherapy containing high-dose methotrexate as the initial treatment. In a multicenter randomized phase 2 trial, high-dose methotrexate with temozolomide was compared to a more aggressive IV regimen consisting KEY POINTS h Intensive chemotherapy followed by autologous stem cell transplantation without whole-brain radiation therapy appears to be a highly effective consolidative approach for primary central nervous system lymphoma, especially in younger patients with good performance status.
h Similar to younger patients, no established standard of care exists for patients with primary central nervous system lymphoma who are elderly; however, it is recommended to omit whole-brain radiation therapy or defer whole-brain radiation therapy to disease relapse and to consider multiagent chemotherapy containing high-dose methotrexate as the initial treatment.
of high-dose methotrexate, procarbazine, vincristine, and cytarabine (MPV-A regimen) in 98 patients who were elderly. 39 No whole-brain radiation therapy was included. Efficacy end points favored the MPV-A arm with respect to median progression-free survival (9.5 versus 6.1 months), overall survival (31 versus 14 months), and objective response rate (82% versus 71%); however, none of these differences reached statistical difference. Toxicities were common but most were reversible, and no difference was seen between the two arms. Quality of life improved in both groups, with no evidence of neurotoxicity. Another prospective phase 2 trial investigated chemoimmunotherapy consisting of rituximab, high-dose methotrexate, procarbazine, and CCNU (lomustine) in elderly patients with primary CNS lymphoma. 40 In this study, objective response rate was 82%, median progression-free survival was 16 months, and overall survival was 17.5 months. Patients younger than 80 years of age had better median overall survival of 29 months compared to 4.3 months in those older than 80 years of age. Toxicities were manageable, with a treatment-related mortality rate of 7%.
REFRACTORY OR RELAPSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA Despite high response rates with initial methotrexate-based treatment, more than half of responders will eventually relapse, as illustrated by Case 5-2. Moreover, about one-fourth of patients with newly diagnosed primary CNS lymphoma fail to respond to the initial treatment. Prognosis of refractory or relapsed primary CNS lymphoma remains poor. A retrospective study reported a median overall survival of 2 months after progression in patients with refractory primary CNS lymphoma and a median overall survival of 3.7 months after relapse in patients who relapsed within the first year of initial therapy. 41 Patients who received high-dose chemotherapy with autologous stem cell transplantation at relapse had a better prognosis; however, they tended to be younger, with better performance status and more chemosensitive disease. About 25% of patients were asymptomatic at relapse, which may explain better Karnofsky Performance Status scores and better survival in this group. This supports the need for neuroimaging surveillance after initial treatment.
Prospective trials in this setting are limited; therefore, the optimal treatment for refractory or relapsed primary CNS lymphoma is poorly defined. The choice of salvage treatment will depend on age, previous treatment and response, performance status, and comorbidities at the time of relapse. Many different agents have been tried, with varying results. These include temozolomide, topotecan, rituximab, rituximab/temozolomide, high-dose chemotherapy with autologous stem cell transplantation, bendamustine, ifosfamide/etoposide, and cisplatin/ cytarabine. Also, a number of novel therapeutic agents are currently being investigated, including temsirolimus, pembrolizumab, ibrutinib, buparlisib, pemetrexed, lenalidomide, and pomalidomide.
High-dose methotrexate rechallenge is an option in patients who previously achieved a prolonged response to this agent (Case 5-2). This approach is supported by retrospective studies in which response was observed in 85% to 91% of patients, with median overall survival of 41 to 62 months after the first relapse. 42, 43 
Case 5-2
A 47-year-old man with a history of hypertension presented with short-term memory problems and confusion, which had progressed over the past few weeks. He also had a mild constant headache and fatigue. Brain MRI revealed a 4.6-cm multilobulated contrast-enhancing right thalamus/periatrial lesion with significant surrounding vasogenic edema ( Figure 5-2) . Stereotactic biopsy was consistent with diffuse large B-cell lymphoma, and extent-of-disease evaluation was negative for extracranial disease. He achieved a complete radiographic response to a high-dose methotrexate/temozolomide/ rituximab combination ( Figure 5-2B) . He then underwent consolidative autologous stem cell transplantation with conditioning thiotepa/busulfan/cyclophosphamide chemotherapy.
Three years later, he developed a persistent left temporal dull headache and progressive confusion similar to his initial presentation of primary central nervous system (CNS) lymphoma. Of note, MRI had shown no recurrence 4 months earlier. Repeat MRI revealed large areas of homogeneous enhancement within the genu of the corpus callosum and left caudate head, with significant surrounding edema and mass effect ( Figure 5-2C) . With high-dose dexamethasone, his symptoms improved. A biopsy was deferred, given the high likelihood of recurrent primary CNS lymphoma based on imaging characteristics, clinical presentation, and improvement on steroids. Extent-of-disease evaluation was again negative for extracranial involvement. He started pemetrexed on a phase 1/2 clinical trial for relapsed primary CNS lymphoma and achieved a partial response. However, the pemetrexed was discontinued because of poor tolerance. He then received a high-dose methotrexate 
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high-dose chemotherapy and autologous stem cell transplantation, this approach is also an option for their relapsed primary CNS lymphoma. In a phase 2 trial of high-dose etoposide and cytarabine followed by high-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide (TBC regimen) and autologous stem cell transplantation, 96% of those who proceeded to transplantation achieved a complete radiographic response. 44 After high-dose chemotherapy and autologous stem cell transplantation, the median progressionfree survival and overall survival were 41.4 months and 58.6 months, respectively. Whole-brain radiation therapy is also an option for patients who have not been treated with this modality previously. In retrospective studies, about 75% of patients responded to salvage whole-brain radiation therapy, with median progression-free survival and overall survival of 10 months and 11 to 19 months, respectively. 20, 45 These efficacy results are comparable to those seen when whole-brain radiation therapy is employed as initial therapy, suggesting that deferring whole-brain radiation therapy until disease recurrence does not affect its efficacy. Delayed neurotoxicity of whole-brain radiation therapy remains a problem in this setting and was observed in 15% to 29% of patients who survived longer than 4 months after whole-brain radiation therapy. 20, 45 Age older than 60 years and shorter time (less than 6 months) between the initial methotrexate-based therapy and the salvage whole-brain radiation therapy were associated with increased risk of neurotoxicity.
MONITORING AND FOLLOW-UP
The majority of recurrences occur within the first 5 years of treatment completion, and most of them recur within the CNS. However, recurrences may be delayed; therefore, continued follow-up for 10 years is recommended. The IPCG's recommendations for follow-up assessments and monitoring are outlined in Table 5-6. 14 CONCLUSION Treatment for primary CNS lymphoma has advanced greatly, with improved survival for this rare and aggressive lymphoma of the CNS. However, longterm survival remains poor, and the optimal treatment approach has yet to be established. Currently, high-dose methotrexate-based chemotherapy is considered the standard induction treatment for newly diagnosed primary CNS lymphoma. Ongoing randomized trials are addressing the roles of rituximab and consolidative treatment using high-dose chemotherapy with autologous stem cell transplantation or reduced-dose whole-brain radiation therapy. With better understanding of rechallenge combined with rituximab and vincristine (procarbazine was not given because of possible drug interaction with his antidepressant). He achieved a complete radiographic response ( Figure 5-2D ) and proceeded to consolidation high-dose cytarabine followed by ifosfamide/carboplatin/etoposide chemotherapy. He continued on observation with no evidence of recurrence or neurologic symptoms at his latest follow-up 4 years later.
Comment. This case illustrates that despite successful initial aggressive treatment, a relapse of primary CNS lymphoma is possible. Therefore, ongoing observation and a high suspicion of recurrence with prompt investigations for new neurologic symptoms are important in management of primary CNS lymphoma. A second complete radiographic response with long-term survival is possible with aggressive treatment, especially in young and otherwise fit patients.
Continued from page 1614 the molecular genetic characteristics of primary CNS lymphoma, individualized treatments that incorporate targeted agents may be the future direction for this disease to improve not only survival, but also patients' quality of life with less toxicity from treatment. 
